ALEXANDRIA, Va., July 30 -- United States Patent no. 12,370,258, issued on July 29, was assigned to Leidos Inc. (Reston, Va.).
"PD-1 and CTLA-4 dual inhibitor peptides" was invented by Gabriel M. Gutierrez (Reston, Va.), Vinayaka Kotraiah (Reston, Va.), Timothy W. Phares (Reston, Va.) and James Pannucci (Reston, Va.).
According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative ...